Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05172687 · ClinicalTrials.gov registry record
The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia
A clinical trial of Alzheimer Disease and Dementia, sponsored by Columbia University.
- Completed
- Registry status
- 336,460
- Enrollment target
- 3
- Study locations
NCT05172687 is a study of Alzheimer Disease and Dementia that has completed, run by Columbia University. The registered enrollment target is 336,460 participants, above the 1,651-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (20279% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT05172687, a study of Alzheimer Disease and Dementia, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 336,460 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia. Using a randomized controlled trial conducted by the Centers for Medicare and Medicaid Services (CMS) in 2015, this secondary study looks at the effects of potential de-prescribing of antipsychotics by study physicians induced by the letters. The central question is whether the intervention led to better health and quality of life outcomes by encouraging more guideline-concordant care and whether changes in physicians' prescription behavior caused unintended harms.
Conditions Studied
Interventions
- BEHAVIORAL Overprescribing letter to attributed physician
- BEHAVIORAL Placebo letter to attributed physician
Study Locations (3)
Massachusetts
- Harvard T.H. Chan School of Public Health - Boston
- National Bureau of Economic Research - Cambridge
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336,460 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05172687
The ClinicalTrials.gov registry entry for NCT05172687 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 336,460 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,651-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (20279% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Overprescribing letter to attributed physician is the first listed.
NCT05172687 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05172687 about?
NCT05172687 is a clinical study titled "The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia". This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia. Using a randomized controlled trial conducted by the Centers for Medicare and Medicaid Services (CMS) in ...
What is the current status of trial NCT05172687?
This trial is currently completed. The enrollment target is 336,460 participants. The study started on 2015-04. Estimated completion is 2018-12-31.
What conditions does trial NCT05172687 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Prescribing, Off-Label.
What interventions are being tested in trial NCT05172687?
The interventions under investigation include: Overprescribing letter to attributed physician (BEHAVIORAL), Placebo letter to attributed physician (BEHAVIORAL).
Who is sponsoring clinical trial NCT05172687?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05172687 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.